CARLSBAD, Calif., and CAMBRIDGE, Mass., March 26, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics, Inc. (Nasdaq: AKCA), today announced Phase 3 data showing that inotersen-treated patients with…
